Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

BeyondSpring Files US/China NDAs for Novel Neutropenia Prevention Drug

publication date: Apr 1, 2021

BeyondSpring, a New York City cancer biopharma, submitted NDAs to US and China regulators of a novel prevention treatment for chemotherapy-induced neutropenia (CIN). The company combines plinabulin with granulocyte colony-stimulating factor (G-CSF), the current standard of care. BeyondSpring says G-CSF treatment is most beneficial in Week 2 after chemotherapy, leaving patients vulnerable during Week 1, the so called “neutropenia vulnerability gap” when over 75% of CIN-related clinical complications occur. More details....

Stock Symbol: (NSDQ: BYSI)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.